蒙古族人群代谢综合征与炎症和内皮功能异常及心脑血管事件的关系
|
摘要
研究目的:
了解内蒙古通辽市农牧区蒙古族人群代谢综合征(MS)的流行状况;探讨MS的危险因素及MS与炎症和内皮功能标志物的关联性;探讨MS以及炎症和内皮功能标志物与心脑血管事件的关联性,为MS和心脑血管疾病的防治提供依据。
研究方法:
横断面研究:于2002-2003年,选择内蒙古通辽市科左后旗朝鲁吐乡和奈曼旗固日班花乡的32个村作为研究现场,现场内所有20岁以上者均作为研究对象,采用面对面调查方法,收集人口统计学以及生活方式资料,测量血压和人体测量指标。采集血标本,并检测血糖、血脂、C反应蛋白(CRP)、细胞间黏附分子-1(ICAM-1)、E选择素(E-selectin)、胰岛素(Ins)、血浆肾素活性(PRA)和血管紧张素II(Ang II)等指标。
随访研究:于2008年和2009年两次对基线调查的人群进行入户随访,收集基线以来的心脑血管事件的发生情况,包括发生的时间、诊断情况及治疗情况。统计分析:
描述蒙古族人群MS的患病情况和分布特征;比较MS组和非MS组危险因素的暴露水平。用两分类反应变量的Logistic回归模型分析各危险因素与MS的关联性,计算比值比(OR)及其95%可信区间(CI)。
将标志物CRP、ICAM-1和E-selectin按四分位数划分为四个组,用Logistic回归模型分析不同标志物水平与MS的关联性,计算OR及95%CI。以各标志物的各四分位组的中位数和OR值为连续变量,用线性回归模型分析各标志物与其对MS危险性的线性趋势。
用累积发病率和发病密度描述心脑血管事件的发生情况;用COX比例风险模型分析MS、CRP、ICAM-1和E-selectin对各心脑血管事件的关联性,计算相对危险度(RR)和95% CI。所有统计分析用SPSS15.0和SAS9.01软件完成,检验水准α=0.05。
研究结果:
1、研究人群的MS的患病率为20.9%(IDF),其中男性为12.8%,女性为26.6%。
2、单因素分析结果显示,年龄、性别(女性)、高血压家族史、高载脂蛋白b、高Ins、PRA异常、高CRP、高ICAM-1、高E-selectin与MS相关联;吸烟和饮酒与MS负相关。多因素分析结果显示,年龄、性别、高CRP、高Ins、PRA异常是MS的危险因素,其OR值(95%CI)分别为1.21(1.07,1.38)、2.39(1.68,3.42)、2.76(2.08,3.66)、1.38(1.04,1.84)、1.35(1.04,1.75),均有P<0.05。吸烟与MS呈负的关联关系,其OR为0.74(0.55,0.99),P<0.05。
3、MS组的CRP、E-selection和ICAM-1的水平显著高于非MS组,均有P<0.05。与最低的CRP水平者相比,经多变量调整后,处于较高CRP水平者(第3和4分位组)对MS的OR(95%CI)分别为1.64(1.00,2.44)和4.36(2.97,6.42),呈剂量反应关系。与最低ICAM-1水平者相比,处于较高ICAM-1水平者(第2、3和4分位组)对MS的OR(95%CI)分别为1.45(1.00,2.10)、1.57(1.09,2.26)和1.72(1.19,2.48),呈显著的剂量反应关系。
4、研究人群随访期间心脑血管疾病累积发病率为3.01%,发病密度为476.9/10万人年;缺血性脑卒中发病率为1.58%,发病密度为250.8/10万人年;出血性脑卒中累积发病率为1.35%,发病密度为213.4/10万人年;冠心病累积发病率为1.31%,发病密度为207.9/10万人年。
5、经多因素调整,MS人群发生心脑血管事件的相对危险度RR值(95%CI)为1.34(0.86,2.08);MS对缺血性脑卒中RR值为2.44(1.21,4.90)。
结论:
1、农牧区蒙古族人群具有较高的MS患病率和心脑血管疾病的发病率,MS和心脑血管疾病已成为影响当地蒙古族居民健康的重要公共卫生问题;
2、高CRP和ICAM-1水平可增加MS危险性,提示炎症和内皮功能异常可能在多代谢异常的发生和发展过程中发挥了重要作用;
3、MS是蒙古族人群心脑血管疾病(尤其是缺血性脑卒中)的重要危险因素。
Objective: To understand the prevalence and distribution characteristics of Metabolic Syndrome (MS) among Mongolian population in rural and animal husbandry Area, Tongliao city, Inner Mongolia; to explore risk factors of MS and association of MS with inflammatory and endothelial biomarkers; to analyze the association between MS, inflammatory and endothelial biomarkers and cardio-cerebrovascular events to provide a basis for prevention and control for MS and cardio-cerebrovascular disease .
Study Methods: A cross sectional study was carried out during 2002-2003. 32 villages of Kezuohou and Naiman banners (counties) were selected as study fields, and all Mongolian people aged 20 or more were served as subjects. Demographic data and lifestyle factors were investigated, anthropometric parameters and blood pressure were measured and blood sample was collected for all subjects. Fasting plasma glucose (FPG) ,blood lipids, CRP、ICAM-1,E-selectin, insulin, plasma rennin activity (PRA), angiotensin II (Ang II) were examined for all subjects. In 2008 and 2009, a follow-up study was conducted for all subjects to collect the data about incidence of cardio-cerebrovascular diseases.
Statistics analysis: Prevalence and distribution characteristics of MS was described among Mongolian population, and levels of risk factors were compared between subjects with MS and without MS. Association of MS with risk factors was analyzed with Logistic regression, and odds ratios (OR) and 95% confident interval (95%CI) were calculated. Levels of CRP、ICAM-1 and E-selectin were grouped according to quartiles, respectively, ORs and 95% CIs of MS associated with CRP、ICAM-1 and E-selectin were calculated using Logistic regression, and trends of OR with level of the biomarkers were analyzed with linear regression model. Accumulative incidence and incidence density for cardio-cerebrovascular diseases were calculated for the Mongolian population; Association of MS, biomarkers including CRP、ICAM-1 and E-selectin with cardio-cerebrovascular diseases were analyzed with Cox regression model, OR and 95%CI were calculated. All analyses were conducted with SAS 9.01 and SPSS 15.0.
Results:
1. Prevalence of MS was 20.9% among the Mongolian people, and 12.8% for males and 26.6% for females.
2. Un-multivariate adjusted results showed that age, gender, family history of hypertension, Apo-b, high Ins, abnormal PRA, high CRP, high ICAM-1, high E-selectin were all associated with MS (all P<0.05). Multivariate adjusted results showed that age, gender, high CRP, high Ins and abnormal PRA were associated with MS, OR(95%CI) of MS associated with age, gender, high CRP, high Ins and abnormal PRA were 1.21 (1.07, 1.38)、2.39(1.68, 3.42)、2.76(2.08, 3.66)、1.38(1.04, 1.84) and 1.35(1.04, 1.75),respectively, all P<0.05.
3. Levels of CRP, E-selectin and ICAM-1 were all higher in MS group than that in non-MS group, all P<0.05. Compared with lowest CRP, the ORs(95%CIs) of MS associated with higher CRP (3 and 4 quartiles ) were 1.64 (1.00, 2.44) and 4.36 (2.97, 6.42), respectively, there was a dose–response relationship between CRP and MS. Compared with lowest ICAM-1 , the ORs (95%CIs) of MS associated with higher ICAM-1 levels ( 2, 3 and 4 quartiles ) were 1.45 (1.00, 2.10), 1.57(1.09, 2.26) and 1.72 (1.19,2.48) , respectively, there was also a dose–response relationship between ICAM-1 levels and MS.
4. Cumulative incidence (CI) and incidence density (ID) of cardio-cerebrovascular disease was 3.01% and 476.9 /100, 000 (person-years), respectively; CI and ID of Ischemic stroke was 1.58% and 250.8/100, 000 (person-years), respectively; CI and ID of hemorrhagic stroke was 1.35%, and 213.4 /100, 000 (person-years), respectively; CI and ID of coronary heart disease was 1.31%, and 207.9 /100, 000 (person-years), respectively.
5. Multivariate adjusted results showed that RR (95 % CI ) of cardio- cerebrovascular events was 1.34 (0.86, 2.08) among the Mongolian population; RR (95 %CI) of Ischemic stroke was 2.44(1.21, 4.90)among the Mongolian population, P<0.05.
Conclusions:
1. There was higher prevalence for MS and higher incidence of cardio-cerebrovascular diseases among the Mongolian population in rural and animal husbandry area, MS and cardio-cerebrovascular diseases have been important public health issue in local area.
2. Elevated CRP and ICAM-1 increase the risk of MS; those findings suggest that inflammation and endothelium dysfunction could play important role in development of MS.
3. MS was an important risk factor of cardio-cerebrovascular diseases, especially ischemic stroke among Mongolian population.
了解内蒙古通辽市农牧区蒙古族人群代谢综合征(MS)的流行状况;探讨MS的危险因素及MS与炎症和内皮功能标志物的关联性;探讨MS以及炎症和内皮功能标志物与心脑血管事件的关联性,为MS和心脑血管疾病的防治提供依据。
研究方法:
横断面研究:于2002-2003年,选择内蒙古通辽市科左后旗朝鲁吐乡和奈曼旗固日班花乡的32个村作为研究现场,现场内所有20岁以上者均作为研究对象,采用面对面调查方法,收集人口统计学以及生活方式资料,测量血压和人体测量指标。采集血标本,并检测血糖、血脂、C反应蛋白(CRP)、细胞间黏附分子-1(ICAM-1)、E选择素(E-selectin)、胰岛素(Ins)、血浆肾素活性(PRA)和血管紧张素II(Ang II)等指标。
随访研究:于2008年和2009年两次对基线调查的人群进行入户随访,收集基线以来的心脑血管事件的发生情况,包括发生的时间、诊断情况及治疗情况。统计分析:
描述蒙古族人群MS的患病情况和分布特征;比较MS组和非MS组危险因素的暴露水平。用两分类反应变量的Logistic回归模型分析各危险因素与MS的关联性,计算比值比(OR)及其95%可信区间(CI)。
将标志物CRP、ICAM-1和E-selectin按四分位数划分为四个组,用Logistic回归模型分析不同标志物水平与MS的关联性,计算OR及95%CI。以各标志物的各四分位组的中位数和OR值为连续变量,用线性回归模型分析各标志物与其对MS危险性的线性趋势。
用累积发病率和发病密度描述心脑血管事件的发生情况;用COX比例风险模型分析MS、CRP、ICAM-1和E-selectin对各心脑血管事件的关联性,计算相对危险度(RR)和95% CI。所有统计分析用SPSS15.0和SAS9.01软件完成,检验水准α=0.05。
研究结果:
1、研究人群的MS的患病率为20.9%(IDF),其中男性为12.8%,女性为26.6%。
2、单因素分析结果显示,年龄、性别(女性)、高血压家族史、高载脂蛋白b、高Ins、PRA异常、高CRP、高ICAM-1、高E-selectin与MS相关联;吸烟和饮酒与MS负相关。多因素分析结果显示,年龄、性别、高CRP、高Ins、PRA异常是MS的危险因素,其OR值(95%CI)分别为1.21(1.07,1.38)、2.39(1.68,3.42)、2.76(2.08,3.66)、1.38(1.04,1.84)、1.35(1.04,1.75),均有P<0.05。吸烟与MS呈负的关联关系,其OR为0.74(0.55,0.99),P<0.05。
3、MS组的CRP、E-selection和ICAM-1的水平显著高于非MS组,均有P<0.05。与最低的CRP水平者相比,经多变量调整后,处于较高CRP水平者(第3和4分位组)对MS的OR(95%CI)分别为1.64(1.00,2.44)和4.36(2.97,6.42),呈剂量反应关系。与最低ICAM-1水平者相比,处于较高ICAM-1水平者(第2、3和4分位组)对MS的OR(95%CI)分别为1.45(1.00,2.10)、1.57(1.09,2.26)和1.72(1.19,2.48),呈显著的剂量反应关系。
4、研究人群随访期间心脑血管疾病累积发病率为3.01%,发病密度为476.9/10万人年;缺血性脑卒中发病率为1.58%,发病密度为250.8/10万人年;出血性脑卒中累积发病率为1.35%,发病密度为213.4/10万人年;冠心病累积发病率为1.31%,发病密度为207.9/10万人年。
5、经多因素调整,MS人群发生心脑血管事件的相对危险度RR值(95%CI)为1.34(0.86,2.08);MS对缺血性脑卒中RR值为2.44(1.21,4.90)。
结论:
1、农牧区蒙古族人群具有较高的MS患病率和心脑血管疾病的发病率,MS和心脑血管疾病已成为影响当地蒙古族居民健康的重要公共卫生问题;
2、高CRP和ICAM-1水平可增加MS危险性,提示炎症和内皮功能异常可能在多代谢异常的发生和发展过程中发挥了重要作用;
3、MS是蒙古族人群心脑血管疾病(尤其是缺血性脑卒中)的重要危险因素。
Objective: To understand the prevalence and distribution characteristics of Metabolic Syndrome (MS) among Mongolian population in rural and animal husbandry Area, Tongliao city, Inner Mongolia; to explore risk factors of MS and association of MS with inflammatory and endothelial biomarkers; to analyze the association between MS, inflammatory and endothelial biomarkers and cardio-cerebrovascular events to provide a basis for prevention and control for MS and cardio-cerebrovascular disease .
Study Methods: A cross sectional study was carried out during 2002-2003. 32 villages of Kezuohou and Naiman banners (counties) were selected as study fields, and all Mongolian people aged 20 or more were served as subjects. Demographic data and lifestyle factors were investigated, anthropometric parameters and blood pressure were measured and blood sample was collected for all subjects. Fasting plasma glucose (FPG) ,blood lipids, CRP、ICAM-1,E-selectin, insulin, plasma rennin activity (PRA), angiotensin II (Ang II) were examined for all subjects. In 2008 and 2009, a follow-up study was conducted for all subjects to collect the data about incidence of cardio-cerebrovascular diseases.
Statistics analysis: Prevalence and distribution characteristics of MS was described among Mongolian population, and levels of risk factors were compared between subjects with MS and without MS. Association of MS with risk factors was analyzed with Logistic regression, and odds ratios (OR) and 95% confident interval (95%CI) were calculated. Levels of CRP、ICAM-1 and E-selectin were grouped according to quartiles, respectively, ORs and 95% CIs of MS associated with CRP、ICAM-1 and E-selectin were calculated using Logistic regression, and trends of OR with level of the biomarkers were analyzed with linear regression model. Accumulative incidence and incidence density for cardio-cerebrovascular diseases were calculated for the Mongolian population; Association of MS, biomarkers including CRP、ICAM-1 and E-selectin with cardio-cerebrovascular diseases were analyzed with Cox regression model, OR and 95%CI were calculated. All analyses were conducted with SAS 9.01 and SPSS 15.0.
Results:
1. Prevalence of MS was 20.9% among the Mongolian people, and 12.8% for males and 26.6% for females.
2. Un-multivariate adjusted results showed that age, gender, family history of hypertension, Apo-b, high Ins, abnormal PRA, high CRP, high ICAM-1, high E-selectin were all associated with MS (all P<0.05). Multivariate adjusted results showed that age, gender, high CRP, high Ins and abnormal PRA were associated with MS, OR(95%CI) of MS associated with age, gender, high CRP, high Ins and abnormal PRA were 1.21 (1.07, 1.38)、2.39(1.68, 3.42)、2.76(2.08, 3.66)、1.38(1.04, 1.84) and 1.35(1.04, 1.75),respectively, all P<0.05.
3. Levels of CRP, E-selectin and ICAM-1 were all higher in MS group than that in non-MS group, all P<0.05. Compared with lowest CRP, the ORs(95%CIs) of MS associated with higher CRP (3 and 4 quartiles ) were 1.64 (1.00, 2.44) and 4.36 (2.97, 6.42), respectively, there was a dose–response relationship between CRP and MS. Compared with lowest ICAM-1 , the ORs (95%CIs) of MS associated with higher ICAM-1 levels ( 2, 3 and 4 quartiles ) were 1.45 (1.00, 2.10), 1.57(1.09, 2.26) and 1.72 (1.19,2.48) , respectively, there was also a dose–response relationship between ICAM-1 levels and MS.
4. Cumulative incidence (CI) and incidence density (ID) of cardio-cerebrovascular disease was 3.01% and 476.9 /100, 000 (person-years), respectively; CI and ID of Ischemic stroke was 1.58% and 250.8/100, 000 (person-years), respectively; CI and ID of hemorrhagic stroke was 1.35%, and 213.4 /100, 000 (person-years), respectively; CI and ID of coronary heart disease was 1.31%, and 207.9 /100, 000 (person-years), respectively.
5. Multivariate adjusted results showed that RR (95 % CI ) of cardio- cerebrovascular events was 1.34 (0.86, 2.08) among the Mongolian population; RR (95 %CI) of Ischemic stroke was 2.44(1.21, 4.90)among the Mongolian population, P<0.05.
Conclusions:
1. There was higher prevalence for MS and higher incidence of cardio-cerebrovascular diseases among the Mongolian population in rural and animal husbandry area, MS and cardio-cerebrovascular diseases have been important public health issue in local area.
2. Elevated CRP and ICAM-1 increase the risk of MS; those findings suggest that inflammation and endothelium dysfunction could play important role in development of MS.
3. MS was an important risk factor of cardio-cerebrovascular diseases, especially ischemic stroke among Mongolian population.
引文
[1] Murray C J, Lopez A D. Mortality by cause for eight regions of the world: Global Burden of Disease Study.[see comment][J]. Lancet, 9061, 349(9061): 1269-1276.
[2] Yao C, Wu Z, Wu Y. The changing pattern of cardiovascular diseases in China[J]. World Health Statistics Quarterly Rapport Trimestriel de Statistiques Sanitaires Mondiales, 1993, 46(2): 113-118.
[3] WHO. Global Burden of Disease WHO 2002: Deaths by age, sex and cause for the year [J]. Geneva, , 2002, Switzerland: World Health Organization,2003
[4] Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies[J]. Circulation, 2001, 04: 2855-2864.
[5] He J, Gu D, Wu X, et al. Major causes of death among men and women in China[J]. N Engl J Med, 2005, 353(11): 1124-1134.
[6] Wei G, Ji X, Bai H, et al. Stroke research in China[J]. Neurol Res, 2006, 28(1): 11-15.
[7] Reaven G M. Banting Lecture 1988. Role of insulin resistance in human disease. 1988[J]. Nutrition, 1997, 13(1).
[8] Gu D, R K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J. Prevalence of the Metabolic Syndrome and Overweight among Adults in China[J]. Lancet 2005, 365(9468): 1398-1405.
[9]顾东风, R K,杨文杰等.中国成年人代谢综合征的患病率[J].中国糖尿病杂志, 2005, 13(3): 181-186.
[10] Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey[J]. Jama, 2002, 287(3): 356-359.
[11] Tan C E, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?[J]. Diabetes Care, 2004, 27(5): 1182-1186.
[12] Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortalityassociated with the metabolic syndrome[J]. Diabetes Care, 2001, 24(4): 683-689.
[13]脑卒中、冠心病发病危险因素进一步研究协作组. 11省市队列人群代谢综合征的流行病学研究[J].中华预防医学杂志, 2002, 36(5): 298-300.
[14] Thomas G N, Ho S Y, Janus E D, et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population[J]. Diabetes Research & Clinical Practice, 2005, 67(3): 251-257.
[15]谭少珍,周智广,唐炜立等.代谢综合征三种诊断标准在2型糖尿病中的比较研究[J].中华糖尿病杂志, 2005, 13(3): 187-189.
[16]向红丁,陈伟,张晓林,方京徽.北京市东城区居民代谢综合征状况的调查[J].中华糖尿病杂志, 2004, 12(3): 169-172.
[17]郭艳英,王坤,赵蕾等.新疆博尔塔拉蒙古自治州维、哈、蒙、汉四民族代谢综合征流行病学调查[J].中华内科杂志, 2006, 145(3): 227-228.
[18]熊英环,金政国,方今女.朝鲜族和汉族人群代谢综合征患病水平及危险因素分析[J].延边大学医学学报, 2007, 30(3): 186-188.
[19]唐振柱,陈兴乐,黄兆勇等.广西城乡居民代谢综合征流行病学特征分析[J].应用预防医学, 2007, 13(6): 325-328.
[20] Zhang M, Batu B, Tong W, et al. Clustering of hyperlipidemia, hyperglycemia, alcohol drinking, overweight and central obesity and hypertension in Mongolian people, China[J]. CVD Prev Control, 2009, 4: 163-169.
[21] Xu T, Ju Z, Tong W,et al. Relationship of C-reactive protein with hypertension and interactions between increased C-reactive protein and other risk factors on hypertension in Mongolian people, China[J]. Circulation Journal, 2008, 72(8): 1324-1328.
[22]呼日勒,胡日乐,张春雨等.内蒙古牧区蒙古族、汉族高血压流行病学调查[J].实用预防医学, 2005, 12(5): 1120-1121.
[23]中国多省市心血管病人群监测研究组.我国人群脑卒中发病率、死亡率的流行病学研究[J].中华流行病学杂志, 2003, 23(3): 236-239.
[24] Zhang C. The role of inflammatory cytokines in endothelial dysfunction[J]. Basic Res Cardiol, 2008, 103(5): 398-406.
[25] Szmitko P E, Wang C H, Weisel R D, et al. New markers of inflammation and endothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[26] Ridker P M, Hennekens C H, Buring J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med, 2000, 342(12): 836-843.
[27] Nabel E G. Biology of the impaired endothelium[J]. Am J Cardiol, 1991, 68(12): 6C-8C.
[28] Sheridan F M, Cole P G, Ramage D. Leukocyte adhesion to the coronary microvasculature during ischemia and reperfusion in an in vivo canine model[J]. Circulation, 1996, 93(10): 1784-1787.
[29] Ohtani H, Strauss H W, Southern J F, et al. Intercellular adhesion molecule-1 induction: a sensitive and quantitative marker for cardiac allograft rejection[J]. J Am Coll Cardiol, 1995, 26(3): 793-799.
[30] Verma S, Li S H, Badiwala M V, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein[J]. Circulation, 2002, 105(16): 1890-1896.
[31] Ross R. Atherosclerosis--an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
[32] Galen F X. Cell adhesion molecules in hypertension: endothelial markers of vascular injury and predictors of target organ damage?[J]. J Hypertens, 2002, 20(5): 813-816.
[33] Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures[J]. J Hypertens, 2003, 21(10): 1841-1846.
[34] Bautista L E, Lopez-Jaramillo P, Vera L M, et al. Is C-reactive protein an independent risk factor for essential hypertension?[J]. J Hypertens, 2001, 19(5): 857-861.
[35] Lakoski S G, Herrington D M, Siscovick D M, et al. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study[J]. Arch Intern Med, 2006, 166(3): 345-349.
[36] Davey Smith G, Lawlor D A, Harbord R.,et_al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality[J]. Arterioscler Thromb Vasc Biol, 2005, 25(5): 1051-1056.
[37] Barzilay J I, Abraham L, Heckbert S R,et_al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study[J]. Diabetes, 2001, 50(10): 2384-2389.
[38] Folsom A R, Aleksic N, Catellier D,et_al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study[J]. Am Heart J, 2002, 144(2): 233-238.
[39] Ridker P M, Rifai N, Rose L,et_al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med, 2002, 347(20): 1557-1565.
[40] Ridker P M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus[J]. J Am Coll Cardiol, 2007, 49(21): 2129-2138.
[41] Carpen O, Pallai P, Staunton D E,et_al. Association of intercellular adhesion molecule-1 (ICAM-1) with actin-containing cytoskeleton and alpha-actinin[J]. Journal of Cell Biology, 1992, 118(5): 1223-1234.
[1]赵仲堂主编.流行病学研究方法与应用.第二版, 2005,科学出版社.
[2] Chalmers J, MacMahon S, Mancia G, et_al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization[J]. Clin Exp Hypertens, 1999, 21(5-6): 1009-1060.
[3]中华心血管病杂志编辑委员会、血脂异常防治对策专题组.血脂异常防治建议[J].中华心血管病杂志, 1997, 25(3): 169-175.
[4]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志, 2007, 35(5): 390.
[5] Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998, 15(7): 539-553.
[6] Federation I D. The IDF consensus worldwide definition of the metabolic syndrome[J]. Available at: http://wwwidforg/ web data/docs/IDF_ Metabolic syndrome definition pdf April 14 2005.
[7] Alexander C M, Landsman, P B, Teutsch, S M, et_al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older[J]. Diabetes, 2003, 52(5): 1210-1214.
[1] Gu D, R K, Wu X, et al. Prevalence of the Metabolic Syndrome and Overweight among Adults in China[J]. Lancet 2005, 365(9468): 1398-1405.
[2]顾东风, R K,杨文杰等.中国成年人代谢综合征的患病率[J].中国糖尿病杂志, 2005, 13(3): 181-186.
[3] Federation I D. The IDF consensus worldwide definition of the metabolic syndrome[J]. Available at: http://wwwidforg/ web data/docs/IDF_ Metabolic syndrome definition pdf Accessed Feb 26 2005.
[4] Alberti K G, Zimmet P, Shaw J, et al. The metabolic syndrome--a new worldwide definition.[see comment][J]. Lancet, 9491, 366(9491): 1059-1062.
[5] Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey[J]. JAMA, 2002, 287(3): 356-359.
[6] Ford E S, Giles W H, Mokdad A H. Increasing prevalence of the metabolic syndrome among u.s. Adults[J]. Diabetes Care, 2004, 27(10): 2444-2449.
[7] Enkhmaa B, Shiwaku K, Anuurad E, et al. Prevalence of the metabolic syndrome using the Third Report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolians[J]. Clinica Chimica Acta, 2005, 352(1-2): 105-113.
[8] Meigs J B, Wilson P W, Nathan D M, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies[J]. Diabetes, 2003, 52(8): 2160-2167.
[9]脑卒中、冠心病发病危险因素进一步研究协作组. 11省市队列人群代谢综合征的流行病学研究[J].中华预防医学杂志, 2002, 36(5): 298-300.
[10] Tan C E, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?[J]. Diabetes Care, 2004, 27(5): 1182-1186.
[11] Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome[J]. Diabetes Care, 2001, 24(4): 683-689.
[12]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志, 2007, 35(5): 390.
[13] Zhang C. The role of inflammatory cytokines in endothelial dysfunction[J]. Basic Res Cardiol, 2008, 103(5): 398-406.
[14] Szmitko P E., Wang C H, Weisel R D, et al. New markers of inflammation and endothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[15] Ridker P M, Hennekens C H, Buring J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med, 2000, 342(12): 836-843.
[16] Glowinska B, Urban M, Peczynska J, et al. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes[J]. Metabolism, 2005, 54(8): 1020-1026.
[17] Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures[J]. J Hypertens, 2003, 21(10): 1841-1846.
[18] Bautista L E, Lopez-Jaramillo P, Vera L M, et al. Is C-reactive protein an independent risk factor for essential hypertension?[J]. J Hypertens, 2001, 19(5): 857-861.
[19] Lakoski S G, Herrington D M, Siscovick D M, et al. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study[J]. Arch Intern Med, 2006, 166(3): 345-349.
[20] Davey Smith G, Lawlor D A, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality[J]. Arterioscler Thromb Vasc Biol, 2005, 25(5): 1051-1056.
[21] Folsom A R, Aleksic N, Catellier D, et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study[J]. AmHeart J, 2002, 144(2): 233-238.
[22] Ridker P M, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med, 2002, 347(20): 1557-1565.
[23] Ridker P M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus[J]. J Am Coll Cardiol, 2007, 49(21): 2129-2138.
[24] Ballantyne C M. Newer risk markers and surrogate endpoints in atherosclerosis management[J]. Clinical Cardiology, 2001, 24(8 Suppl): III13-17.
[25] Ridker P M, Hennekens, C H, Buring, J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. New England Journal of Medicine, 2000, 342(12): 836-843.
[26] Cottone S, Mule G, Nardi E, et al. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension[J]. Journal of Hypertension, 2007, 25(2): 423-428.
[27] Blann A D, Tse W, Maxwell S J, et al. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension[J]. Journal of Hypertension, 1994, 12(8): 925-928.
[28] Hlubocka Z, Umnerova V, Heller S, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors.[see comment][J]. Journal of Human Hypertension, 2002, 16(8): 557-562.
[29] Barzilay J I, Abraham L, Heckbert S R, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study[J]. Diabetes, 2001, 50(10): 2384-2389.
[30] Ridker P M, Ridker P M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus[J]. Journal of the American College of Cardiology, 2007, 49(21): 2129-2138.
[31]黄婼,黄崭,李静,苗红,周莹.代谢综合征患者血清ICAM-1、sCD_(40)水平变化及意义[J].山东医药, 2008, 48(29): 100.
[32] Tamakoshi K, Yatsuya H, Kondo T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state[J]. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity, 2003, 27(4): 443-449.
[33] Festa A, D'Agostino R, Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)[J]. Circulation, 2000, 102(1): 42-47.
[34] Szmitko P E, Wang C H, Weisel R D, et al. New markers of inflammation and endothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[35] Ridker P M, Buring J E, Cook N R, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women[J]. Circulation, 2003, 107(3): 391-397.
[36] Han T S, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study.[see comment][J]. Diabetes Care, 2002, 25(11): 2016-2021.
[37] Lim S, Lee H K, Kimm K C, et al. C-reactive protein level as an independent risk factor of metabolic syndrome in the Korean population. CRP as risk factor of metabolic syndrome[J]. Diabetes Res Clin Pract, 2005, 70(2): 126-133.
[38] Bluher M, Unger R, Rassoul F, et al. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes[J]. Diabetologia, 2002, 45(2): 210-216.
[39]章建梁,秦永文,郑兴等.血清可溶性E选择素水平与血压的相关性研究[J].上海医学, 2004, 27(1): 7-9.
[40] Kowalski J, Okopien B, Madej A, et al. Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia[J]. Int J Clin Pharmacol Ther, 2003, 41(6): 241-247.
[41] Kvasnicka T, Kvasnicka J, Ceska R, et al. Increasing plasma levels of soluble cell adhesion molecules (sE-Selectin, sP-Selectin and sICAM-1) in overweight adults with combined hyperlipidemia[J]. Sb Lek, 2001, 102(4): 473-477.
[42] Pasceri V, Willerson J T, Yeh E T. Direct proinflammatory effect of C-reactive protein on human endothelial cells.[see comment][J]. Circulation, 2000, 102(18): 2165-2168.
[43] Ross R. Atherosclerosis--an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
[44] Sinisalo J, Paronen J, Mattila K J, et al. Relation of inflammation to vascular function in patients with coronary heart disease[J]. Atherosclerosis, 2000, 149(2): 403-411.
[45] Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo[J]. Circulation, 1997, 96(9): 3042-3047.
[46] Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?[J]. Lancet, 1997, 349(9062): 1391-1392.
[47]王艳华,佟伟军,刘永跃,许群,黄桂蓉,张永红.蒙古族人肾素-血管紧张素活性与原发性高血压[J].中国公共卫生, 2005, 21(6): 641-643.
[48]梅仁彪.高血压矿工血浆肾素、血管紧张素Ⅱ、醛固酮和皮质醇水平的分析[J].中国工业医学杂志, 2004, 17(4): 220-223.
[49] Sowers J R. Hypertension, angiotensin II, and oxidative stress[J]. N Engl J Med, 2002, 346(25): 1999-2001.
[50] Schiffrin E L, Touyz R M. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade[J]. J Am Coll Cardiol, 2003, 42(5): 911-913.
[51] Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo[J]. Circulation, 1999, 100(15): 1646-1652.
[52] Dzau V J. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis[J]. Hypertension, 2001, 37(4): 1047-1052.
[53] Liao T D, Yang X P, Liu Y H, et al. Role of inflammation in the development ofrenal damage and dysfunction in angiotensin II-induced hypertension[J]. Hypertension, 2008, 52(2): 256-263.
[54] Velloso L A, Folli F, Sun X J, et al. Cross-talk between the insulin and angiotensin signaling systems[J]. Proc Natl Acad Sci U S A, 1996, 93(22): 12490-12495.
[55] Lim H S, MacFadyen R J, Lip G Y, et al. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart[J]. Archives of Internal Medicine, 2004, 164(16): 1737-1748.
[56]罗素芬,晋学庆.肾素-血管紧张素系统与代谢综合征研究进展[J].医学综述, 2009, 15(2): 464-466.
[57] Zhang YH, Thompson AM, Tong WJ, et al. Biomarkers of inflammation and endothelial dysfunction and risk of hypertension among Inner Mongolians in China[J]. Hypertens 2010, 28(35-40).
[58] Nakanishi N, Yoshida H, Nakamura K, et al. Alcohol consumption and risk for hypertension in middle-aged Japanese men[J]. J Hypertens, 2001, 19(5): 851-855.
[59] Zhang M, Batu B, Tong W, et al. Clustering of hyperlipidemia, hyperglycemia, alcohol drinking, overweight and central obesity and hypertension in Mongolian people, China[J]. CVD Prev Control, 2009, 4: 163-169.
[60] Nakanishi N, Suzuki K, Tatara K. Alcohol consumption and risk for development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men[J]. Diabetes Care, 2003, 26(1): 48-54.
[61] Wannamethee S G, Camargo C A, Jr, Manson J E, et al. Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women[J]. Arch Intern Med, 2003, 163(11): 1329-1336.
[62] Bell R A, Mayer-Davis E J, Martin M A, et al. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin Resistance and Atherosclerosis Study[J]. Diabetes Care, 2000, 23(11): 1630-1636.
[63] Cordain L, Melby C L, Hamamoto A E, et al. Influence of moderate chronic wine consumption on insulin sensitivity and other correlates of syndrome X in moderately obese women[J]. Metabolism, 2000, 49(11): 1473-1478.
[64]张建,华琦,李静等.代谢综合征.北京:人民卫生出版社, 2003: 621.
[65] Attvall S, Fowelin J, Lager I, et al. Smoking induces insulin resistance--a potential link with the insulin resistance syndrome[J]. J Intern Med, 1993, 233(4): 327-332.
[66] Kong C, Nimmo L, Elatrozy T, et al. Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes[J]. Atherosclerosis, 2001, 156(2): 373-378.
[67] Barrett-Connor E, Khaw K T. Cigarette smoking and increased central adiposity[J]. Ann Intern Med, 1989, 111(10): 783-787.
[68] Uchimoto S, Tsumura K, Hayashi T, et al. Impact of cigarette smoking on the incidence of Type 2 diabetes mellitus in middle-aged Japanese men: the Osaka Health Survey[J]. Diabet Med, 1999, 16(11): 951-955.
[69] Smith U. Smoking elicits the insulin resistance syndrome: new aspects of the harmful effect of smoking[J]. J Intern Med, 1995, 237(5): 435-437.
[70] Benowitz N L, Kuy, F, Jacob P, 3rd. Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking[J]. Clin Pharmacol Ther, 1984, 36(1): 74-81.
[71] Comstock G W, Stone R W. Changes in body weight and subcutaneous fatness related to smoking habits[J]. Arch Environ Health, 1972, 24(4): 271-276.
[72]王继旺,张素华,任伟,杜娟,陈静,包柄楠.吸烟与代谢综合征的相关性调查与分析[J].重庆医学, 2004, 33(3): 382-384.
[73]张曙云,俞小忠,黄龑等.吸烟与代谢综合征相关性研究[J].现代中西医结合杂志, 2009, 18(22): 3.
[74] Li H, Tong W, Wang A, et al. Effects of cigarette smoking on blood pressure stratified by BMI in Mongolian population, China[J]. Blood Press, 2010.
[75]周正元,孙国祥,吴国强等.代谢综合征相关危险因素分析[J].上海预防医学杂志, 2006, 18(2): 62-63.
[76]吴桂贤,吴兆苏,刘静等. 11省市代谢综合征患者中心脑血管病发病率队列研究[J].中华流行病学杂志, 2003, 24(7): 551-553.
[77]中国多省市心血管病人群监测研究组.我国人群脑卒中发病率、死亡率的流行病学研究[J].中华流行病学杂志, 2003, 23(3): 236-239.
[78]张晓萍,王印坤,汪关宝等.北京中关村地区1984-2000年急性冠心病事件的流行病学研究[J].心肺血管病杂志, 2007, 26(3): 139-131.
[79]郭琳芳,李业生,徐永芳等.南宁市城区居民连续13年高血压、脑卒中、冠心病发病趋势分析[J].现代预防医学, 2006, 33(6): 944-945.
[80] Noto D, Barbagallo C M, Cefalu A B, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population[J]. Atherosclerosis, 2008, 197(1): 147-153.
[81] Boden-Albala B, Sacco R L, Lee H S, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study.[see comment][J]. Stroke, 2008, 39(1): 30-35.
[82] Takahashi K, Bokura H, Kobayashi S, et al. Metabolic syndrome increases the risk of ischemic stroke in women[J]. Internal Medicine, 2007, 46(10): 643-648.
[83] Malik S, Wong N D, Franklin S S, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults[J]. Circulation, 2004, 110(10): 1245-1250.
[84] Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study[J]. Circulation, 2003, 108(4): 414-419.
[85] Reynolds G D, Vance R P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas[J]. Arch Pathol Lab Med, 1987, 111(3): 265-269.
[86] Hatanaka K, Li X A, Masuda K, et al. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method[J]. Pathol Int, 1995, 45(9): 635-641.
[87] Torzewski J, Torzewski M, Bowyer D E, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries[J]. Arterioscler Thromb Vasc Biol, 1998, 18(9): 1386-1392.
[88]李雪梅,刘美萍,刘百波等.血清超敏C-反应蛋白与老年急性缺血性脑卒中的关系[J].神经疾病和精神卫生, 2004, 4(6): 448-449.
[89] Ridker P M, Cushman M, Stampfer M J, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men[J]. N Engl J Med, 1997, 336(14): 973-979.
[90] Rost N S, Wolf P A, Kase C S, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study[J]. Stroke, 2001, 32(11): 2575-2579.
[91] Haverkate F, Thompson S G, Pyke S D, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group[J]. Lancet, 1997, 349(9050): 462-466.
[92] Shyu K G, Chang H, Lin C C. Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke[J]. J Neurol, 1997, 244(2): 90-93.
[93]宋水江,闻树群,黄鉴政.缺血性脑卒中血清可溶性细胞间粘附分子-1的含量变化[J]. 2003, 2003, 32(1): 57-58.
[94] Blankenberg S, Rupprecht H J, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease[J]. Circulation, 2001, 104(12): 1336-1342.
[95] Semaan H B, Gurbel P A, Anderson J L, et al. Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease[J]. Cardiology, 2000, 93(1-2): 7-10.
[96]荣海钦.代谢综合征还是慢性炎症综合征[J].实用糖尿病杂志, 2006, 3(1): 3-5.
[1] Meigs J B. Epidemiology of the metabolic syndrome, 2002[J]. Am J Manag Care, 2002, 8(11 Suppl): S283-292; quiz S293-286.
[2] Gorter P M, Olijhoek J K, Van der Graaf Y, et al. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm[J]. Atherosclerosis, 2004, 173(2): 363-369.
[3] Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome[J]. Diabetes Care, 2001, 24(4): 683-689.
[4] Lakka H M, Laaksonen D E, Lakka T A, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men[J]. JAMA, 2002, 288(21): 2709-2716.
[5] Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease[J]. Diabetes, 1988, 37(12): 1595-1607.
[6] Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998, 15(7): 539-553.
[7] Thomas G N, Ho S Y, Janus E D, et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population[J]. Diabetes Research & Clinical Practice, 2005, 67(3): 251-257.
[8] Federation I D. The IDF consensus worldwide definition of the metabolic syndrome[J]. Available at: http://wwwidforg/ web data/docs/IDF_ Metabolic syndrome definition pdf Accessed Feb 26.
[9]顾东风, R K,杨文杰等.中国成年人代谢综合征的患病率[J].中国糖尿病杂志, 2005, 13(3): 181-186.
[10]谭少珍,周智广,唐炜立等.代谢综合征三种诊断标准在2型糖尿病中的比较研究[J].中华糖尿病杂志, 2005, 13(3): 187-189.
[11] Pei D, Kuo S W, Wu D A, et al. The relationships between insulin resistance and components of metabolic syndrome in Taiwanese Asians[J]. Int J Clin Pract, 2005, 59(12): 1408-1416.
[12] Lee I T, Lin T M, Lee W J, et al. Hypercholesterolemia, not metabolic syndrome, related to adhesion of monocytes to cultured endothelium in nondiabetic subjects[J]. Metabolism, 2005, 54(11): 1467-1471.
[13]贾伟平.中国人群胰岛素抵抗的状况[J].国外医学内分泌学分册, 2002, 22(4): 1.
[14] Liese A D, Mayer-Davis E J, Tyroler H A, et al. Familial components of the multiple metabolic syndrome: the ARIC study[J]. Diabetologia, 1997, 40(8): 963-970.
[15] Chen W, Srinivasan S R, Elkasabany, A, et al. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (Syndrome X) between young parents and their offspring: the Bogalusa Heart Study[J]. Atherosclerosis, 1999, 145(1): 197-205.
[16] Burke G L, Savage P J, Sprafka J M, et al. Relation of risk factor levels in young adulthood to parental history of disease. The CARDIA study[J]. Circulation, 1991, 84(3): 1176-1187.
[17] Carmelli D, Cardon L R, Fabsitz R. Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments?[J]. Am J Hum Genet, 1994, 55(3): 566-573.
[18] Mitchell B D, Kammerer C M, Mahaney, M C, et al. Genetic analysis of the IRS. Pleiotropic effects of genes influencing insulin levels on lipoprotein and obesity measures[J]. Arterioscler Thromb Vasc Biol, 1996, 16(2): 281-288.
[19] Edwards K L, Newman B, Mayer E, et al. Heritability of factors of the insulin resistance syndrome in women twins[J]. Genet Epidemiol, 1997, 14(3): 241-253.
[20] Zimmet P, Alberti K G, Shaw J. Global and societal implications of the diabetes epidemic[J]. Nature, 2001, 414(6865): 782-787.
[21] Mayer-Davis E J, D'Agostino R, Jr, Karter A J, et al. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin ResistanceAtherosclerosis Study[J]. JAMA, 1998, 279(9): 669-674.
[22] Whaley M H, Kampert J B, Kohl H W, 3rd, et al. Physical fitness and clustering of risk factors associated with the metabolic syndrome[J]. Med Sci Sports Exerc, 1999, 31(2): 287-293.
[23] Laaksonen D E, Lakka H M, Salonen J T, et al. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome[J]. Diabetes Care, 2002, 25(9): 1612-1618.
[24]王继旺,张素华,汪志红等.吸烟与胰岛素抵抗关系的实验研究[J].中国糖尿病杂志, 2007, 15(1): 52-55
[25]李秀钧.糖尿病抵抗综合征.人民卫生出版社, 2001,北京.
[26] Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey[J]. Jama, 2002, 287(3): 356-359.
[27] Ford E S, Giles W H, Mokdad A H. Increasing prevalence of the metabolic syndrome among u.s. Adults[J]. Diabetes Care, 2004, 27(10): 2444-2449.
[28] Gu D, R K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J. Prevalence of the Metabolic Syndrome and Overweight among Adults in China[J]. Lancet 2005, 365(9468): 1398-1405.
[29] Federation I D. The IDF consensus worldwide definition of the metabolic syndrome[J]. Available at: http://wwwidforg/ web data/docs/IDF_ Metabolic syndrome definition pdf Accessed Feb 26 2005.
[30] Alberti K G, Zimmet P, Shaw J, et al. The metabolic syndrome--a new worldwide definition.[see comment][J]. Lancet, 9491, 366(9491): 1059-1062.
[31] Enkhmaa B, Shiwaku K, Anuurad E, et al. Prevalence of the metabolic syndrome using the Third Report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolians[J]. Clinica Chimica Acta, 2005, 352(1-2): 105-113.
[32] Meigs J B, Wilson P W, Nathan D M, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham OffspringStudies[J]. Diabetes, 2003, 52(8): 2160-2167.
[33] Tan C E, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?[J]. Diabetes Care, 2004, 27(5): 1182-1186.
[34]贾伟平,项坤三,陈蕾等.两种MS工作定义在上海地区人群中应用的比较[J].中华医学杂志, 2004, 84(7): 534-538.
[35]脑卒中、冠心病发病危险因素进一步研究协作组. 11省市队列人群MS的流行病学研究[J].中华预防医学杂志, 2002, 36(5): 298-300.
[36]向红丁,陈伟,张晓林,方京徽.北京市东城区居民MS状况的调查[J].中华糖尿病杂志, 2004, 12(3): 169-172.
[37]郭艳英,王坤,赵蕾,敖由特,徐翀,沙根德克·耶里节夫,何秉贤.新疆博尔塔拉蒙古自治州维、哈、蒙、汉四民族MS流行病学调查[J].中华内科杂志, 2006, 145(3): 227-228.
[38]徐乐超,任西珍,郑诚东.成年人MS及相关因素的调查研究[J].中华名医论坛, 2005, (2): 55-56.
[39]欧阳凤秀,姜庆五,俞顺章等. MS危险因素研究[J].中国公共卫生, 2004, 20(3): 312-313.
[40]国家“九五”攻关计划糖尿病研究协作组.中国12个地区中老年人糖尿病患病率调查[J].中华内分泌代谢杂志, 2002, (18): 280-284.
[41]马湘俊,陈君柱.代谢综合征危险因子与早期干预[J].中国心血管病研究杂志, 2005, 5(3): 395-398.
[42]张曙云,俞小忠,黄龑,陶君,吴晓虹,朱辰,胡柏成.吸烟与MS相关性研究[J].现代中西医结合杂志, 2009, 18(22): 3.
[43]于淑清,文仪.青少年吸烟可增加代谢综合征的发病风险[J].国外医学情报, 2006, 27: 121-122.
[44]范建高,朱军,李新建等.上海市成人饮酒与代谢综合征关系的流行病学调查[J].肝脏, 2005, 10(1): 11-15.
[45] Athyros V G, Liberopoulos E N, Mikhailidis D P, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in aMediterranean cohort[J]. Angiology, 2007, 58(6): 689-697.
[46] Fan A Z, Russell M, Dorn J, et al. Lifetime alcohol drinking pattern is related to the prevalence of metabolic syndrome. The Western New York Health Study (WNYHS)[J]. Eur J Epidemiol, 2006, 21(2): 129-138.
[47] Liu S, Manson J E. Dietary carbohydrates, physical inactivity, obesity, and the 'metabolic syndrome' as predictors of coronary heart disease[J]. Curr Opin Lipidol, 2001, 12(4): 395-404.
[48]张刚,祝之明,赵志刚等.代谢综合征危险因素的特征[J].高血压杂志, 2004, 12(1): 83-86.
[49] Mittendorfer B, Sidossis L S. Mechanism for the increase in plasma triacylglycerol concentrations after consumption of short-term, high-carbohydrate diets[J]. Am J Clin Nutr, 2001, 73(5): 892-899.
[50]刘道燕,余争平,张刚等.重庆地区代谢综合征的环境和遗传因素危险性分析[J].重庆医学, 2005, 34(1): 51-53.
[51] Mohan V, Shanthirani S, Deepa R, et al. Intra-urban differences in the prevalence of the metabolic syndrome in southern India -- the Chennai Urban Population Study (CUPS No. 4)[J]. Diabet Med, 2001, 18(4): 280-287.
[52]刘新军,徐延敏.代谢综合征与心血管疾病相关的危险因素及防治策略[J].实用心脑肺血管病杂志, 2004, 6(12): 365-367.
[53] Rutter M K, Meigs J B, Sullivan L M, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study[J]. Circulation, 2004, 110(4): 380-385.
[54] Wannamethee S G, Lowe G D, Shaper A G, et al. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men[J]. Atherosclerosis, 2005, 181(1): 101-108.
[55] Ford E S. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey[J]. Atherosclerosis, 2003, 168(2): 351-358.
[56] Lee W Y, Park J S, Noh S Y, et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report[J].International Journal of Cardiology, 2004, 97(1): 101-106.
[57] Yudkin J S, Stehouwer C D, Emeis J J, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?[J]. Arteriosclerosis, Thrombosis & Vascular Biology, 1999, 19(4): 972-978.
[58] Sesso H D, Buring J E, Rifai N, et al. C-reactive protein and the risk of developing hypertension.[see comment][J]. JAMA, 2003, 290(22): 2945-2951.
[59]荣海钦.代谢综合征还是慢性炎症综合征[J].实用糖尿病杂志, 2006, 3(1): 3-5.
[60] Tamakoshi K, Yatsuya H, Kondo T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state[J]. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity, 2003, 27(4): 443-449.
[61] Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)[J]. Circulation, 2000, 102(1): 42-47.
[62] Szmitko P E, Wang C H, Weisel R D, et al. New markers of inflammation and endothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[63] Ridker P M, Buring J E, Cook N R, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women[J]. Circulation, 2003, 107(3): 391-397.
[64]章建梁,秦永文,郑兴,等.血清可溶性E选择素水平与血压的相关性研究[J].上海医学, 2004, 27(1): 7-9.
[65] Glowinska B, Urban M, Peczynska J, et al. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes[J]. Metabolism, 2005, 54(8): 1020-1026.
[66] Zhang C. The role of inflammatory cytokines in endothelial dysfunction[J]. Basic Res Cardiol, 2008, 103(5): 398-406.
[67] Szmitko P E, Wang C H, Weisel R D, et al. New markers of inflammation andendothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[68] Ridker P M, Hennekens C H, Buring J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med, 2000, 342(12): 836-843.
[69] Reynolds G. D, Vance R P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas[J]. Arch Pathol Lab Med, 1987, 111(3): 265-269.
[70] Hatanaka K, Li X A, Masuda K, et al. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method[J]. Pathol Int, 1995, 45(9): 635-641.
[71] Torzewski J, Torzewski M, Bowyer D E, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries[J]. Arterioscler Thromb Vasc Biol, 1998, 18(9): 1386-1392.
[72]李雪梅,刘美萍,刘百波等.血清超敏C-反应蛋白与老年急性缺血性脑卒中的关系[J].神经疾病和精神卫生, 2004, 4(6): 448-449.
[73] Ridker P M, Cushman M, Stampfer M J, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men[J]. N Engl J Med, 1997, 336(14): 973-979.
[74] Rost N S, Wolf P A, Kase C S, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study[J]. Stroke, 2001, 32(11): 2575-2579.
[75] Haverkate F, Thompson S G., Pyke S D, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group[J]. Lancet, 1997, 349(9050): 462-466.
[76] Haidari M, Hajilooi M, Rafiei A R, et al. E-selectin genetic variation as a susceptibility factor for ischemic stroke[J]. Cerebrovasc Dis, 2009, 28(1): 26-32.
[77] Shyu K G., Chang H, Lin C C. Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke[J]. J Neurol, 1997, 244(2):90-93.
[78]宋水江,闻树群,黄鉴政.缺血性脑卒中血清可溶性细胞间粘附分子-1的含量变化[J]. 2003, 2003, 32(1): 57-58.
[79] Blankenberg S, Rupprecht H J, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease[J]. Circulation, 2001, 104(12): 1336-1342.
[80] Semaan H B, Gurbel P A, Anderson J L, et al. Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease[J]. Cardiology, 2000, 93(1-2): 7-10.
[81] Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study[J]. J Am Coll Cardiol, 2002, 39(7): 1133-1138.
[82] McNeill A M, Rosamond W D, Girman C J, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study[J]. Diabetes Care, 2005, 28(2): 385-390.
[83] Wen C J, Lee Y S, Lin W Y, et al. The metabolic syndrome increases cardiovascular mortality in Taiwanese elderly[J]. European Journal of Clinical Investigation, 2008, 38(7): 469-475.
[84] Noto D, Barbagallo C M, Cefalu A B, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population[J]. Atherosclerosis, 2008, 197(1): 147-153.
[85] Malik S, Wong N D, Franklin S S, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults[J]. Circulation, 2004, 110(10): 1245-1250.
[86] Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study[J]. Circulation, 2003, 108(4): 414-419.
[87] He Y, Jiang B, Wang J, et al. Prevalence of the metabolic syndrome and its relationto cardiovascular disease in an elderly Chinese population[J]. Journal of the American College of Cardiology, 2006, 47(8): 1588-1594.
[88] Ford E S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S[J]. Diabetes Care, 2005, 28(11): 2745-2749.
[89] Ford E S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study[J]. Atherosclerosis, 2004, 173(2): 309-314.
[90]吴桂贤,吴兆苏,刘静等. 11省市代谢综合征患者中心脑血管病发病率队列研究[J].中华流行病学杂志, 2003, 24(7): 551-553.
[91] Boden-Albala B, Sacco R L, Lee H S, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study.[see comment][J]. Stroke, 2008, 39(1): 30-35.
[92] Takahashi K, Bokura H, Kobayashi S, et al. Metabolic syndrome increases the risk of ischemic stroke in women[J]. Internal Medicine, 2007, 46(10): 643-648.
[93] Schulze M B, Hu F B. Dietary approaches to prevent the metabolic syndrome: quality versus quantity of carbohydrates[J]. Diabetes Care, 2004, 27(2): 613-614.
[94]孙冬玲,顾东风.代谢综合征的干预和转归[J].中国实用内科杂志, 2008 28(11): 907-909.
[95] Kahn S E, Haffner S M, Heise M A, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy[J]. N Engl J Med, 2006, 355(23): 2427-2443.
[96] Nissen S E, Nicholls S J, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial[J]. JAMA, 2008, 299(13): 1547-1560.
[2] Yao C, Wu Z, Wu Y. The changing pattern of cardiovascular diseases in China[J]. World Health Statistics Quarterly Rapport Trimestriel de Statistiques Sanitaires Mondiales, 1993, 46(2): 113-118.
[3] WHO. Global Burden of Disease WHO 2002: Deaths by age, sex and cause for the year [J]. Geneva, , 2002, Switzerland: World Health Organization,2003
[4] Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies[J]. Circulation, 2001, 04: 2855-2864.
[5] He J, Gu D, Wu X, et al. Major causes of death among men and women in China[J]. N Engl J Med, 2005, 353(11): 1124-1134.
[6] Wei G, Ji X, Bai H, et al. Stroke research in China[J]. Neurol Res, 2006, 28(1): 11-15.
[7] Reaven G M. Banting Lecture 1988. Role of insulin resistance in human disease. 1988[J]. Nutrition, 1997, 13(1).
[8] Gu D, R K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J. Prevalence of the Metabolic Syndrome and Overweight among Adults in China[J]. Lancet 2005, 365(9468): 1398-1405.
[9]顾东风, R K,杨文杰等.中国成年人代谢综合征的患病率[J].中国糖尿病杂志, 2005, 13(3): 181-186.
[10] Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey[J]. Jama, 2002, 287(3): 356-359.
[11] Tan C E, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?[J]. Diabetes Care, 2004, 27(5): 1182-1186.
[12] Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortalityassociated with the metabolic syndrome[J]. Diabetes Care, 2001, 24(4): 683-689.
[13]脑卒中、冠心病发病危险因素进一步研究协作组. 11省市队列人群代谢综合征的流行病学研究[J].中华预防医学杂志, 2002, 36(5): 298-300.
[14] Thomas G N, Ho S Y, Janus E D, et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population[J]. Diabetes Research & Clinical Practice, 2005, 67(3): 251-257.
[15]谭少珍,周智广,唐炜立等.代谢综合征三种诊断标准在2型糖尿病中的比较研究[J].中华糖尿病杂志, 2005, 13(3): 187-189.
[16]向红丁,陈伟,张晓林,方京徽.北京市东城区居民代谢综合征状况的调查[J].中华糖尿病杂志, 2004, 12(3): 169-172.
[17]郭艳英,王坤,赵蕾等.新疆博尔塔拉蒙古自治州维、哈、蒙、汉四民族代谢综合征流行病学调查[J].中华内科杂志, 2006, 145(3): 227-228.
[18]熊英环,金政国,方今女.朝鲜族和汉族人群代谢综合征患病水平及危险因素分析[J].延边大学医学学报, 2007, 30(3): 186-188.
[19]唐振柱,陈兴乐,黄兆勇等.广西城乡居民代谢综合征流行病学特征分析[J].应用预防医学, 2007, 13(6): 325-328.
[20] Zhang M, Batu B, Tong W, et al. Clustering of hyperlipidemia, hyperglycemia, alcohol drinking, overweight and central obesity and hypertension in Mongolian people, China[J]. CVD Prev Control, 2009, 4: 163-169.
[21] Xu T, Ju Z, Tong W,et al. Relationship of C-reactive protein with hypertension and interactions between increased C-reactive protein and other risk factors on hypertension in Mongolian people, China[J]. Circulation Journal, 2008, 72(8): 1324-1328.
[22]呼日勒,胡日乐,张春雨等.内蒙古牧区蒙古族、汉族高血压流行病学调查[J].实用预防医学, 2005, 12(5): 1120-1121.
[23]中国多省市心血管病人群监测研究组.我国人群脑卒中发病率、死亡率的流行病学研究[J].中华流行病学杂志, 2003, 23(3): 236-239.
[24] Zhang C. The role of inflammatory cytokines in endothelial dysfunction[J]. Basic Res Cardiol, 2008, 103(5): 398-406.
[25] Szmitko P E, Wang C H, Weisel R D, et al. New markers of inflammation and endothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[26] Ridker P M, Hennekens C H, Buring J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med, 2000, 342(12): 836-843.
[27] Nabel E G. Biology of the impaired endothelium[J]. Am J Cardiol, 1991, 68(12): 6C-8C.
[28] Sheridan F M, Cole P G, Ramage D. Leukocyte adhesion to the coronary microvasculature during ischemia and reperfusion in an in vivo canine model[J]. Circulation, 1996, 93(10): 1784-1787.
[29] Ohtani H, Strauss H W, Southern J F, et al. Intercellular adhesion molecule-1 induction: a sensitive and quantitative marker for cardiac allograft rejection[J]. J Am Coll Cardiol, 1995, 26(3): 793-799.
[30] Verma S, Li S H, Badiwala M V, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein[J]. Circulation, 2002, 105(16): 1890-1896.
[31] Ross R. Atherosclerosis--an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
[32] Galen F X. Cell adhesion molecules in hypertension: endothelial markers of vascular injury and predictors of target organ damage?[J]. J Hypertens, 2002, 20(5): 813-816.
[33] Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures[J]. J Hypertens, 2003, 21(10): 1841-1846.
[34] Bautista L E, Lopez-Jaramillo P, Vera L M, et al. Is C-reactive protein an independent risk factor for essential hypertension?[J]. J Hypertens, 2001, 19(5): 857-861.
[35] Lakoski S G, Herrington D M, Siscovick D M, et al. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study[J]. Arch Intern Med, 2006, 166(3): 345-349.
[36] Davey Smith G, Lawlor D A, Harbord R.,et_al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality[J]. Arterioscler Thromb Vasc Biol, 2005, 25(5): 1051-1056.
[37] Barzilay J I, Abraham L, Heckbert S R,et_al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study[J]. Diabetes, 2001, 50(10): 2384-2389.
[38] Folsom A R, Aleksic N, Catellier D,et_al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study[J]. Am Heart J, 2002, 144(2): 233-238.
[39] Ridker P M, Rifai N, Rose L,et_al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med, 2002, 347(20): 1557-1565.
[40] Ridker P M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus[J]. J Am Coll Cardiol, 2007, 49(21): 2129-2138.
[41] Carpen O, Pallai P, Staunton D E,et_al. Association of intercellular adhesion molecule-1 (ICAM-1) with actin-containing cytoskeleton and alpha-actinin[J]. Journal of Cell Biology, 1992, 118(5): 1223-1234.
[1]赵仲堂主编.流行病学研究方法与应用.第二版, 2005,科学出版社.
[2] Chalmers J, MacMahon S, Mancia G, et_al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization[J]. Clin Exp Hypertens, 1999, 21(5-6): 1009-1060.
[3]中华心血管病杂志编辑委员会、血脂异常防治对策专题组.血脂异常防治建议[J].中华心血管病杂志, 1997, 25(3): 169-175.
[4]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志, 2007, 35(5): 390.
[5] Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998, 15(7): 539-553.
[6] Federation I D. The IDF consensus worldwide definition of the metabolic syndrome[J]. Available at: http://wwwidforg/ web data/docs/IDF_ Metabolic syndrome definition pdf April 14 2005.
[7] Alexander C M, Landsman, P B, Teutsch, S M, et_al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older[J]. Diabetes, 2003, 52(5): 1210-1214.
[1] Gu D, R K, Wu X, et al. Prevalence of the Metabolic Syndrome and Overweight among Adults in China[J]. Lancet 2005, 365(9468): 1398-1405.
[2]顾东风, R K,杨文杰等.中国成年人代谢综合征的患病率[J].中国糖尿病杂志, 2005, 13(3): 181-186.
[3] Federation I D. The IDF consensus worldwide definition of the metabolic syndrome[J]. Available at: http://wwwidforg/ web data/docs/IDF_ Metabolic syndrome definition pdf Accessed Feb 26 2005.
[4] Alberti K G, Zimmet P, Shaw J, et al. The metabolic syndrome--a new worldwide definition.[see comment][J]. Lancet, 9491, 366(9491): 1059-1062.
[5] Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey[J]. JAMA, 2002, 287(3): 356-359.
[6] Ford E S, Giles W H, Mokdad A H. Increasing prevalence of the metabolic syndrome among u.s. Adults[J]. Diabetes Care, 2004, 27(10): 2444-2449.
[7] Enkhmaa B, Shiwaku K, Anuurad E, et al. Prevalence of the metabolic syndrome using the Third Report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolians[J]. Clinica Chimica Acta, 2005, 352(1-2): 105-113.
[8] Meigs J B, Wilson P W, Nathan D M, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies[J]. Diabetes, 2003, 52(8): 2160-2167.
[9]脑卒中、冠心病发病危险因素进一步研究协作组. 11省市队列人群代谢综合征的流行病学研究[J].中华预防医学杂志, 2002, 36(5): 298-300.
[10] Tan C E, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?[J]. Diabetes Care, 2004, 27(5): 1182-1186.
[11] Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome[J]. Diabetes Care, 2001, 24(4): 683-689.
[12]中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中华心血管病杂志, 2007, 35(5): 390.
[13] Zhang C. The role of inflammatory cytokines in endothelial dysfunction[J]. Basic Res Cardiol, 2008, 103(5): 398-406.
[14] Szmitko P E., Wang C H, Weisel R D, et al. New markers of inflammation and endothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[15] Ridker P M, Hennekens C H, Buring J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med, 2000, 342(12): 836-843.
[16] Glowinska B, Urban M, Peczynska J, et al. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes[J]. Metabolism, 2005, 54(8): 1020-1026.
[17] Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures[J]. J Hypertens, 2003, 21(10): 1841-1846.
[18] Bautista L E, Lopez-Jaramillo P, Vera L M, et al. Is C-reactive protein an independent risk factor for essential hypertension?[J]. J Hypertens, 2001, 19(5): 857-861.
[19] Lakoski S G, Herrington D M, Siscovick D M, et al. C-reactive protein concentration and incident hypertension in young adults: the CARDIA study[J]. Arch Intern Med, 2006, 166(3): 345-349.
[20] Davey Smith G, Lawlor D A, Harbord R, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality[J]. Arterioscler Thromb Vasc Biol, 2005, 25(5): 1051-1056.
[21] Folsom A R, Aleksic N, Catellier D, et al. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study[J]. AmHeart J, 2002, 144(2): 233-238.
[22] Ridker P M, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events[J]. N Engl J Med, 2002, 347(20): 1557-1565.
[23] Ridker P M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus[J]. J Am Coll Cardiol, 2007, 49(21): 2129-2138.
[24] Ballantyne C M. Newer risk markers and surrogate endpoints in atherosclerosis management[J]. Clinical Cardiology, 2001, 24(8 Suppl): III13-17.
[25] Ridker P M, Hennekens, C H, Buring, J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. New England Journal of Medicine, 2000, 342(12): 836-843.
[26] Cottone S, Mule G, Nardi E, et al. C-reactive protein and intercellular adhesion molecule-1 are stronger predictors of oxidant stress than blood pressure in established hypertension[J]. Journal of Hypertension, 2007, 25(2): 423-428.
[27] Blann A D, Tse W, Maxwell S J, et al. Increased levels of the soluble adhesion molecule E-selectin in essential hypertension[J]. Journal of Hypertension, 1994, 12(8): 925-928.
[28] Hlubocka Z, Umnerova V, Heller S, et al. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors.[see comment][J]. Journal of Human Hypertension, 2002, 16(8): 557-562.
[29] Barzilay J I, Abraham L, Heckbert S R, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study[J]. Diabetes, 2001, 50(10): 2384-2389.
[30] Ridker P M, Ridker P M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus[J]. Journal of the American College of Cardiology, 2007, 49(21): 2129-2138.
[31]黄婼,黄崭,李静,苗红,周莹.代谢综合征患者血清ICAM-1、sCD_(40)水平变化及意义[J].山东医药, 2008, 48(29): 100.
[32] Tamakoshi K, Yatsuya H, Kondo T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state[J]. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity, 2003, 27(4): 443-449.
[33] Festa A, D'Agostino R, Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)[J]. Circulation, 2000, 102(1): 42-47.
[34] Szmitko P E, Wang C H, Weisel R D, et al. New markers of inflammation and endothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[35] Ridker P M, Buring J E, Cook N R, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women[J]. Circulation, 2003, 107(3): 391-397.
[36] Han T S, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study.[see comment][J]. Diabetes Care, 2002, 25(11): 2016-2021.
[37] Lim S, Lee H K, Kimm K C, et al. C-reactive protein level as an independent risk factor of metabolic syndrome in the Korean population. CRP as risk factor of metabolic syndrome[J]. Diabetes Res Clin Pract, 2005, 70(2): 126-133.
[38] Bluher M, Unger R, Rassoul F, et al. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes[J]. Diabetologia, 2002, 45(2): 210-216.
[39]章建梁,秦永文,郑兴等.血清可溶性E选择素水平与血压的相关性研究[J].上海医学, 2004, 27(1): 7-9.
[40] Kowalski J, Okopien B, Madej A, et al. Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia[J]. Int J Clin Pharmacol Ther, 2003, 41(6): 241-247.
[41] Kvasnicka T, Kvasnicka J, Ceska R, et al. Increasing plasma levels of soluble cell adhesion molecules (sE-Selectin, sP-Selectin and sICAM-1) in overweight adults with combined hyperlipidemia[J]. Sb Lek, 2001, 102(4): 473-477.
[42] Pasceri V, Willerson J T, Yeh E T. Direct proinflammatory effect of C-reactive protein on human endothelial cells.[see comment][J]. Circulation, 2000, 102(18): 2165-2168.
[43] Ross R. Atherosclerosis--an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
[44] Sinisalo J, Paronen J, Mattila K J, et al. Relation of inflammation to vascular function in patients with coronary heart disease[J]. Atherosclerosis, 2000, 149(2): 403-411.
[45] Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo[J]. Circulation, 1997, 96(9): 3042-3047.
[46] Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?[J]. Lancet, 1997, 349(9062): 1391-1392.
[47]王艳华,佟伟军,刘永跃,许群,黄桂蓉,张永红.蒙古族人肾素-血管紧张素活性与原发性高血压[J].中国公共卫生, 2005, 21(6): 641-643.
[48]梅仁彪.高血压矿工血浆肾素、血管紧张素Ⅱ、醛固酮和皮质醇水平的分析[J].中国工业医学杂志, 2004, 17(4): 220-223.
[49] Sowers J R. Hypertension, angiotensin II, and oxidative stress[J]. N Engl J Med, 2002, 346(25): 1999-2001.
[50] Schiffrin E L, Touyz R M. Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade[J]. J Am Coll Cardiol, 2003, 42(5): 911-913.
[51] Pastore L, Tessitore A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo[J]. Circulation, 1999, 100(15): 1646-1652.
[52] Dzau V J. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis[J]. Hypertension, 2001, 37(4): 1047-1052.
[53] Liao T D, Yang X P, Liu Y H, et al. Role of inflammation in the development ofrenal damage and dysfunction in angiotensin II-induced hypertension[J]. Hypertension, 2008, 52(2): 256-263.
[54] Velloso L A, Folli F, Sun X J, et al. Cross-talk between the insulin and angiotensin signaling systems[J]. Proc Natl Acad Sci U S A, 1996, 93(22): 12490-12495.
[55] Lim H S, MacFadyen R J, Lip G Y, et al. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart[J]. Archives of Internal Medicine, 2004, 164(16): 1737-1748.
[56]罗素芬,晋学庆.肾素-血管紧张素系统与代谢综合征研究进展[J].医学综述, 2009, 15(2): 464-466.
[57] Zhang YH, Thompson AM, Tong WJ, et al. Biomarkers of inflammation and endothelial dysfunction and risk of hypertension among Inner Mongolians in China[J]. Hypertens 2010, 28(35-40).
[58] Nakanishi N, Yoshida H, Nakamura K, et al. Alcohol consumption and risk for hypertension in middle-aged Japanese men[J]. J Hypertens, 2001, 19(5): 851-855.
[59] Zhang M, Batu B, Tong W, et al. Clustering of hyperlipidemia, hyperglycemia, alcohol drinking, overweight and central obesity and hypertension in Mongolian people, China[J]. CVD Prev Control, 2009, 4: 163-169.
[60] Nakanishi N, Suzuki K, Tatara K. Alcohol consumption and risk for development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men[J]. Diabetes Care, 2003, 26(1): 48-54.
[61] Wannamethee S G, Camargo C A, Jr, Manson J E, et al. Alcohol drinking patterns and risk of type 2 diabetes mellitus among younger women[J]. Arch Intern Med, 2003, 163(11): 1329-1336.
[62] Bell R A, Mayer-Davis E J, Martin M A, et al. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin Resistance and Atherosclerosis Study[J]. Diabetes Care, 2000, 23(11): 1630-1636.
[63] Cordain L, Melby C L, Hamamoto A E, et al. Influence of moderate chronic wine consumption on insulin sensitivity and other correlates of syndrome X in moderately obese women[J]. Metabolism, 2000, 49(11): 1473-1478.
[64]张建,华琦,李静等.代谢综合征.北京:人民卫生出版社, 2003: 621.
[65] Attvall S, Fowelin J, Lager I, et al. Smoking induces insulin resistance--a potential link with the insulin resistance syndrome[J]. J Intern Med, 1993, 233(4): 327-332.
[66] Kong C, Nimmo L, Elatrozy T, et al. Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes[J]. Atherosclerosis, 2001, 156(2): 373-378.
[67] Barrett-Connor E, Khaw K T. Cigarette smoking and increased central adiposity[J]. Ann Intern Med, 1989, 111(10): 783-787.
[68] Uchimoto S, Tsumura K, Hayashi T, et al. Impact of cigarette smoking on the incidence of Type 2 diabetes mellitus in middle-aged Japanese men: the Osaka Health Survey[J]. Diabet Med, 1999, 16(11): 951-955.
[69] Smith U. Smoking elicits the insulin resistance syndrome: new aspects of the harmful effect of smoking[J]. J Intern Med, 1995, 237(5): 435-437.
[70] Benowitz N L, Kuy, F, Jacob P, 3rd. Influence of nicotine on cardiovascular and hormonal effects of cigarette smoking[J]. Clin Pharmacol Ther, 1984, 36(1): 74-81.
[71] Comstock G W, Stone R W. Changes in body weight and subcutaneous fatness related to smoking habits[J]. Arch Environ Health, 1972, 24(4): 271-276.
[72]王继旺,张素华,任伟,杜娟,陈静,包柄楠.吸烟与代谢综合征的相关性调查与分析[J].重庆医学, 2004, 33(3): 382-384.
[73]张曙云,俞小忠,黄龑等.吸烟与代谢综合征相关性研究[J].现代中西医结合杂志, 2009, 18(22): 3.
[74] Li H, Tong W, Wang A, et al. Effects of cigarette smoking on blood pressure stratified by BMI in Mongolian population, China[J]. Blood Press, 2010.
[75]周正元,孙国祥,吴国强等.代谢综合征相关危险因素分析[J].上海预防医学杂志, 2006, 18(2): 62-63.
[76]吴桂贤,吴兆苏,刘静等. 11省市代谢综合征患者中心脑血管病发病率队列研究[J].中华流行病学杂志, 2003, 24(7): 551-553.
[77]中国多省市心血管病人群监测研究组.我国人群脑卒中发病率、死亡率的流行病学研究[J].中华流行病学杂志, 2003, 23(3): 236-239.
[78]张晓萍,王印坤,汪关宝等.北京中关村地区1984-2000年急性冠心病事件的流行病学研究[J].心肺血管病杂志, 2007, 26(3): 139-131.
[79]郭琳芳,李业生,徐永芳等.南宁市城区居民连续13年高血压、脑卒中、冠心病发病趋势分析[J].现代预防医学, 2006, 33(6): 944-945.
[80] Noto D, Barbagallo C M, Cefalu A B, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population[J]. Atherosclerosis, 2008, 197(1): 147-153.
[81] Boden-Albala B, Sacco R L, Lee H S, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study.[see comment][J]. Stroke, 2008, 39(1): 30-35.
[82] Takahashi K, Bokura H, Kobayashi S, et al. Metabolic syndrome increases the risk of ischemic stroke in women[J]. Internal Medicine, 2007, 46(10): 643-648.
[83] Malik S, Wong N D, Franklin S S, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults[J]. Circulation, 2004, 110(10): 1245-1250.
[84] Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study[J]. Circulation, 2003, 108(4): 414-419.
[85] Reynolds G D, Vance R P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas[J]. Arch Pathol Lab Med, 1987, 111(3): 265-269.
[86] Hatanaka K, Li X A, Masuda K, et al. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method[J]. Pathol Int, 1995, 45(9): 635-641.
[87] Torzewski J, Torzewski M, Bowyer D E, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries[J]. Arterioscler Thromb Vasc Biol, 1998, 18(9): 1386-1392.
[88]李雪梅,刘美萍,刘百波等.血清超敏C-反应蛋白与老年急性缺血性脑卒中的关系[J].神经疾病和精神卫生, 2004, 4(6): 448-449.
[89] Ridker P M, Cushman M, Stampfer M J, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men[J]. N Engl J Med, 1997, 336(14): 973-979.
[90] Rost N S, Wolf P A, Kase C S, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study[J]. Stroke, 2001, 32(11): 2575-2579.
[91] Haverkate F, Thompson S G, Pyke S D, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group[J]. Lancet, 1997, 349(9050): 462-466.
[92] Shyu K G, Chang H, Lin C C. Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke[J]. J Neurol, 1997, 244(2): 90-93.
[93]宋水江,闻树群,黄鉴政.缺血性脑卒中血清可溶性细胞间粘附分子-1的含量变化[J]. 2003, 2003, 32(1): 57-58.
[94] Blankenberg S, Rupprecht H J, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease[J]. Circulation, 2001, 104(12): 1336-1342.
[95] Semaan H B, Gurbel P A, Anderson J L, et al. Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease[J]. Cardiology, 2000, 93(1-2): 7-10.
[96]荣海钦.代谢综合征还是慢性炎症综合征[J].实用糖尿病杂志, 2006, 3(1): 3-5.
[1] Meigs J B. Epidemiology of the metabolic syndrome, 2002[J]. Am J Manag Care, 2002, 8(11 Suppl): S283-292; quiz S293-286.
[2] Gorter P M, Olijhoek J K, Van der Graaf Y, et al. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm[J]. Atherosclerosis, 2004, 173(2): 363-369.
[3] Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome[J]. Diabetes Care, 2001, 24(4): 683-689.
[4] Lakka H M, Laaksonen D E, Lakka T A, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men[J]. JAMA, 2002, 288(21): 2709-2716.
[5] Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease[J]. Diabetes, 1988, 37(12): 1595-1607.
[6] Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998, 15(7): 539-553.
[7] Thomas G N, Ho S Y, Janus E D, et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population[J]. Diabetes Research & Clinical Practice, 2005, 67(3): 251-257.
[8] Federation I D. The IDF consensus worldwide definition of the metabolic syndrome[J]. Available at: http://wwwidforg/ web data/docs/IDF_ Metabolic syndrome definition pdf Accessed Feb 26.
[9]顾东风, R K,杨文杰等.中国成年人代谢综合征的患病率[J].中国糖尿病杂志, 2005, 13(3): 181-186.
[10]谭少珍,周智广,唐炜立等.代谢综合征三种诊断标准在2型糖尿病中的比较研究[J].中华糖尿病杂志, 2005, 13(3): 187-189.
[11] Pei D, Kuo S W, Wu D A, et al. The relationships between insulin resistance and components of metabolic syndrome in Taiwanese Asians[J]. Int J Clin Pract, 2005, 59(12): 1408-1416.
[12] Lee I T, Lin T M, Lee W J, et al. Hypercholesterolemia, not metabolic syndrome, related to adhesion of monocytes to cultured endothelium in nondiabetic subjects[J]. Metabolism, 2005, 54(11): 1467-1471.
[13]贾伟平.中国人群胰岛素抵抗的状况[J].国外医学内分泌学分册, 2002, 22(4): 1.
[14] Liese A D, Mayer-Davis E J, Tyroler H A, et al. Familial components of the multiple metabolic syndrome: the ARIC study[J]. Diabetologia, 1997, 40(8): 963-970.
[15] Chen W, Srinivasan S R, Elkasabany, A, et al. The association of cardiovascular risk factor clustering related to insulin resistance syndrome (Syndrome X) between young parents and their offspring: the Bogalusa Heart Study[J]. Atherosclerosis, 1999, 145(1): 197-205.
[16] Burke G L, Savage P J, Sprafka J M, et al. Relation of risk factor levels in young adulthood to parental history of disease. The CARDIA study[J]. Circulation, 1991, 84(3): 1176-1187.
[17] Carmelli D, Cardon L R, Fabsitz R. Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments?[J]. Am J Hum Genet, 1994, 55(3): 566-573.
[18] Mitchell B D, Kammerer C M, Mahaney, M C, et al. Genetic analysis of the IRS. Pleiotropic effects of genes influencing insulin levels on lipoprotein and obesity measures[J]. Arterioscler Thromb Vasc Biol, 1996, 16(2): 281-288.
[19] Edwards K L, Newman B, Mayer E, et al. Heritability of factors of the insulin resistance syndrome in women twins[J]. Genet Epidemiol, 1997, 14(3): 241-253.
[20] Zimmet P, Alberti K G, Shaw J. Global and societal implications of the diabetes epidemic[J]. Nature, 2001, 414(6865): 782-787.
[21] Mayer-Davis E J, D'Agostino R, Jr, Karter A J, et al. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin ResistanceAtherosclerosis Study[J]. JAMA, 1998, 279(9): 669-674.
[22] Whaley M H, Kampert J B, Kohl H W, 3rd, et al. Physical fitness and clustering of risk factors associated with the metabolic syndrome[J]. Med Sci Sports Exerc, 1999, 31(2): 287-293.
[23] Laaksonen D E, Lakka H M, Salonen J T, et al. Low levels of leisure-time physical activity and cardiorespiratory fitness predict development of the metabolic syndrome[J]. Diabetes Care, 2002, 25(9): 1612-1618.
[24]王继旺,张素华,汪志红等.吸烟与胰岛素抵抗关系的实验研究[J].中国糖尿病杂志, 2007, 15(1): 52-55
[25]李秀钧.糖尿病抵抗综合征.人民卫生出版社, 2001,北京.
[26] Ford E S, Giles W H, Dietz W H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey[J]. Jama, 2002, 287(3): 356-359.
[27] Ford E S, Giles W H, Mokdad A H. Increasing prevalence of the metabolic syndrome among u.s. Adults[J]. Diabetes Care, 2004, 27(10): 2444-2449.
[28] Gu D, R K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J. Prevalence of the Metabolic Syndrome and Overweight among Adults in China[J]. Lancet 2005, 365(9468): 1398-1405.
[29] Federation I D. The IDF consensus worldwide definition of the metabolic syndrome[J]. Available at: http://wwwidforg/ web data/docs/IDF_ Metabolic syndrome definition pdf Accessed Feb 26 2005.
[30] Alberti K G, Zimmet P, Shaw J, et al. The metabolic syndrome--a new worldwide definition.[see comment][J]. Lancet, 9491, 366(9491): 1059-1062.
[31] Enkhmaa B, Shiwaku K, Anuurad E, et al. Prevalence of the metabolic syndrome using the Third Report of the National Cholesterol Educational Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III) and the modified ATP III definitions for Japanese and Mongolians[J]. Clinica Chimica Acta, 2005, 352(1-2): 105-113.
[32] Meigs J B, Wilson P W, Nathan D M, et al. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham OffspringStudies[J]. Diabetes, 2003, 52(8): 2160-2167.
[33] Tan C E, Ma S, Wai D, et al. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?[J]. Diabetes Care, 2004, 27(5): 1182-1186.
[34]贾伟平,项坤三,陈蕾等.两种MS工作定义在上海地区人群中应用的比较[J].中华医学杂志, 2004, 84(7): 534-538.
[35]脑卒中、冠心病发病危险因素进一步研究协作组. 11省市队列人群MS的流行病学研究[J].中华预防医学杂志, 2002, 36(5): 298-300.
[36]向红丁,陈伟,张晓林,方京徽.北京市东城区居民MS状况的调查[J].中华糖尿病杂志, 2004, 12(3): 169-172.
[37]郭艳英,王坤,赵蕾,敖由特,徐翀,沙根德克·耶里节夫,何秉贤.新疆博尔塔拉蒙古自治州维、哈、蒙、汉四民族MS流行病学调查[J].中华内科杂志, 2006, 145(3): 227-228.
[38]徐乐超,任西珍,郑诚东.成年人MS及相关因素的调查研究[J].中华名医论坛, 2005, (2): 55-56.
[39]欧阳凤秀,姜庆五,俞顺章等. MS危险因素研究[J].中国公共卫生, 2004, 20(3): 312-313.
[40]国家“九五”攻关计划糖尿病研究协作组.中国12个地区中老年人糖尿病患病率调查[J].中华内分泌代谢杂志, 2002, (18): 280-284.
[41]马湘俊,陈君柱.代谢综合征危险因子与早期干预[J].中国心血管病研究杂志, 2005, 5(3): 395-398.
[42]张曙云,俞小忠,黄龑,陶君,吴晓虹,朱辰,胡柏成.吸烟与MS相关性研究[J].现代中西医结合杂志, 2009, 18(22): 3.
[43]于淑清,文仪.青少年吸烟可增加代谢综合征的发病风险[J].国外医学情报, 2006, 27: 121-122.
[44]范建高,朱军,李新建等.上海市成人饮酒与代谢综合征关系的流行病学调查[J].肝脏, 2005, 10(1): 11-15.
[45] Athyros V G, Liberopoulos E N, Mikhailidis D P, et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in aMediterranean cohort[J]. Angiology, 2007, 58(6): 689-697.
[46] Fan A Z, Russell M, Dorn J, et al. Lifetime alcohol drinking pattern is related to the prevalence of metabolic syndrome. The Western New York Health Study (WNYHS)[J]. Eur J Epidemiol, 2006, 21(2): 129-138.
[47] Liu S, Manson J E. Dietary carbohydrates, physical inactivity, obesity, and the 'metabolic syndrome' as predictors of coronary heart disease[J]. Curr Opin Lipidol, 2001, 12(4): 395-404.
[48]张刚,祝之明,赵志刚等.代谢综合征危险因素的特征[J].高血压杂志, 2004, 12(1): 83-86.
[49] Mittendorfer B, Sidossis L S. Mechanism for the increase in plasma triacylglycerol concentrations after consumption of short-term, high-carbohydrate diets[J]. Am J Clin Nutr, 2001, 73(5): 892-899.
[50]刘道燕,余争平,张刚等.重庆地区代谢综合征的环境和遗传因素危险性分析[J].重庆医学, 2005, 34(1): 51-53.
[51] Mohan V, Shanthirani S, Deepa R, et al. Intra-urban differences in the prevalence of the metabolic syndrome in southern India -- the Chennai Urban Population Study (CUPS No. 4)[J]. Diabet Med, 2001, 18(4): 280-287.
[52]刘新军,徐延敏.代谢综合征与心血管疾病相关的危险因素及防治策略[J].实用心脑肺血管病杂志, 2004, 6(12): 365-367.
[53] Rutter M K, Meigs J B, Sullivan L M, et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study[J]. Circulation, 2004, 110(4): 380-385.
[54] Wannamethee S G, Lowe G D, Shaper A G, et al. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men[J]. Atherosclerosis, 2005, 181(1): 101-108.
[55] Ford E S. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey[J]. Atherosclerosis, 2003, 168(2): 351-358.
[56] Lee W Y, Park J S, Noh S Y, et al. C-reactive protein concentrations are related to insulin resistance and metabolic syndrome as defined by the ATP III report[J].International Journal of Cardiology, 2004, 97(1): 101-106.
[57] Yudkin J S, Stehouwer C D, Emeis J J, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?[J]. Arteriosclerosis, Thrombosis & Vascular Biology, 1999, 19(4): 972-978.
[58] Sesso H D, Buring J E, Rifai N, et al. C-reactive protein and the risk of developing hypertension.[see comment][J]. JAMA, 2003, 290(22): 2945-2951.
[59]荣海钦.代谢综合征还是慢性炎症综合征[J].实用糖尿病杂志, 2006, 3(1): 3-5.
[60] Tamakoshi K, Yatsuya H, Kondo T, et al. The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state[J]. International Journal of Obesity & Related Metabolic Disorders: Journal of the International Association for the Study of Obesity, 2003, 27(4): 443-449.
[61] Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)[J]. Circulation, 2000, 102(1): 42-47.
[62] Szmitko P E, Wang C H, Weisel R D, et al. New markers of inflammation and endothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[63] Ridker P M, Buring J E, Cook N R, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women[J]. Circulation, 2003, 107(3): 391-397.
[64]章建梁,秦永文,郑兴,等.血清可溶性E选择素水平与血压的相关性研究[J].上海医学, 2004, 27(1): 7-9.
[65] Glowinska B, Urban M, Peczynska J, et al. Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes[J]. Metabolism, 2005, 54(8): 1020-1026.
[66] Zhang C. The role of inflammatory cytokines in endothelial dysfunction[J]. Basic Res Cardiol, 2008, 103(5): 398-406.
[67] Szmitko P E, Wang C H, Weisel R D, et al. New markers of inflammation andendothelial cell activation: Part I[J]. Circulation, 2003, 108(16): 1917-1923.
[68] Ridker P M, Hennekens C H, Buring J E, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women[J]. N Engl J Med, 2000, 342(12): 836-843.
[69] Reynolds G. D, Vance R P. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas[J]. Arch Pathol Lab Med, 1987, 111(3): 265-269.
[70] Hatanaka K, Li X A, Masuda K, et al. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method[J]. Pathol Int, 1995, 45(9): 635-641.
[71] Torzewski J, Torzewski M, Bowyer D E, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries[J]. Arterioscler Thromb Vasc Biol, 1998, 18(9): 1386-1392.
[72]李雪梅,刘美萍,刘百波等.血清超敏C-反应蛋白与老年急性缺血性脑卒中的关系[J].神经疾病和精神卫生, 2004, 4(6): 448-449.
[73] Ridker P M, Cushman M, Stampfer M J, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men[J]. N Engl J Med, 1997, 336(14): 973-979.
[74] Rost N S, Wolf P A, Kase C S, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study[J]. Stroke, 2001, 32(11): 2575-2579.
[75] Haverkate F, Thompson S G., Pyke S D, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group[J]. Lancet, 1997, 349(9050): 462-466.
[76] Haidari M, Hajilooi M, Rafiei A R, et al. E-selectin genetic variation as a susceptibility factor for ischemic stroke[J]. Cerebrovasc Dis, 2009, 28(1): 26-32.
[77] Shyu K G., Chang H, Lin C C. Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke[J]. J Neurol, 1997, 244(2):90-93.
[78]宋水江,闻树群,黄鉴政.缺血性脑卒中血清可溶性细胞间粘附分子-1的含量变化[J]. 2003, 2003, 32(1): 57-58.
[79] Blankenberg S, Rupprecht H J, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease[J]. Circulation, 2001, 104(12): 1336-1342.
[80] Semaan H B, Gurbel P A, Anderson J L, et al. Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease[J]. Cardiology, 2000, 93(1-2): 7-10.
[81] Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study[J]. J Am Coll Cardiol, 2002, 39(7): 1133-1138.
[82] McNeill A M, Rosamond W D, Girman C J, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study[J]. Diabetes Care, 2005, 28(2): 385-390.
[83] Wen C J, Lee Y S, Lin W Y, et al. The metabolic syndrome increases cardiovascular mortality in Taiwanese elderly[J]. European Journal of Clinical Investigation, 2008, 38(7): 469-475.
[84] Noto D, Barbagallo C M, Cefalu A B, et al. The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a Mediterranean population[J]. Atherosclerosis, 2008, 197(1): 147-153.
[85] Malik S, Wong N D, Franklin S S, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults[J]. Circulation, 2004, 110(10): 1245-1250.
[86] Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study[J]. Circulation, 2003, 108(4): 414-419.
[87] He Y, Jiang B, Wang J, et al. Prevalence of the metabolic syndrome and its relationto cardiovascular disease in an elderly Chinese population[J]. Journal of the American College of Cardiology, 2006, 47(8): 1588-1594.
[88] Ford E S. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S[J]. Diabetes Care, 2005, 28(11): 2745-2749.
[89] Ford E S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study[J]. Atherosclerosis, 2004, 173(2): 309-314.
[90]吴桂贤,吴兆苏,刘静等. 11省市代谢综合征患者中心脑血管病发病率队列研究[J].中华流行病学杂志, 2003, 24(7): 551-553.
[91] Boden-Albala B, Sacco R L, Lee H S, et al. Metabolic syndrome and ischemic stroke risk: Northern Manhattan Study.[see comment][J]. Stroke, 2008, 39(1): 30-35.
[92] Takahashi K, Bokura H, Kobayashi S, et al. Metabolic syndrome increases the risk of ischemic stroke in women[J]. Internal Medicine, 2007, 46(10): 643-648.
[93] Schulze M B, Hu F B. Dietary approaches to prevent the metabolic syndrome: quality versus quantity of carbohydrates[J]. Diabetes Care, 2004, 27(2): 613-614.
[94]孙冬玲,顾东风.代谢综合征的干预和转归[J].中国实用内科杂志, 2008 28(11): 907-909.
[95] Kahn S E, Haffner S M, Heise M A, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy[J]. N Engl J Med, 2006, 355(23): 2427-2443.
[96] Nissen S E, Nicholls S J, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial[J]. JAMA, 2008, 299(13): 1547-1560.